Skip to main content

Table 2 Outcomes per cohort of 1000 critically ill patients with suspected nosocomial candidemia

From: Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation

Outcome

Point estimate

95% confidence interval*

Empiric MIC compared with empiric FLU

  

   Deaths averted

4

2 to 13

   Incremental cost/death averted†

$61,446

$43,821 to $80,039

   Incremental cost/life year saved†¶

$22,230

$18,201 to $26,088

   Incremental cost/QALY†¶

$34,734

$26,312 to $49,209

Empiric MIC compared with watchful waiting strategy

  

   Deaths averted

29

11 to 69

   Incremental cost/death averted†

$9,892

$3,771 to $26,065

   Incremental cost/life year saved†¶

$17,777

$14,174 to $21,360

   Incremental cost/QALY†¶

$27,777

$20,572 to $39,888

Empiric FLU compared with watchful waiting strategy

  

   Deaths averted

25

9 to 57

   Incremental cost/death averted†

$1,704

$640 to $4,839

   Incremental cost/life year saved†¶

$17,070

$13,582 to $20,436

   Incremental cost/QALY†¶

$26,672

$19,699 to $38,223

  1. *From the Monte Carlo simulations, 10,000 trials for each outcome.
  2. †All costs inflated to 2008 $US using medical component of the consumer price index.
  3. ¶Costs incorporating lifetime estimates are discounted at 3% per annum (range 0 to 6%)
  4. FLU = fluconazole; MIC = micafungin; QALY = quality-adjusted life year.
Back to article page

Critical Care

ISSN: 1364-8535